209 related articles for article (PubMed ID: 33046892)
1. Targetable gene fusions and aberrations in genitourinary oncology.
Pederzoli F; Bandini M; Marandino L; Ali SM; Madison R; Chung J; Ross JS; Necchi A
Nat Rev Urol; 2020 Nov; 17(11):613-625. PubMed ID: 33046892
[TBL] [Abstract][Full Text] [Related]
2. Gene and immune-based therapies for genitourinary malignancies: current status and future prospects.
Zisman A; Pantuck AJ; Belldegrun A
Isr Med Assoc J; 2000 Jan; 2(1):33-42. PubMed ID: 10892369
[No Abstract] [Full Text] [Related]
3. Potential use of RNA interference as therapeutic strategy in urologic cancer.
Green WJ; James PA; Ratan HL
Urology; 2011 Sep; 78(3):500-4. PubMed ID: 21741681
[No Abstract] [Full Text] [Related]
4. Oncogenic FGFR3 gene fusions in bladder cancer.
Williams SV; Hurst CD; Knowles MA
Hum Mol Genet; 2013 Feb; 22(4):795-803. PubMed ID: 23175443
[TBL] [Abstract][Full Text] [Related]
5. Latest progress in molecular biology and treatment in genitourinary tumours.
González-Del-Alba A; Arranz JÁ; Bellmunt J; Maroto JP; Fernández-Calvo O; Valderrama BP; González-Billalabeitia E; Méndez-Vidal MJ; Cassinello J; Romero-Laorden N; Climent MÁ; Puente J; Peláez I; Lázaro-Quintela M; Gallardo E; Suárez C
Clin Transl Oncol; 2020 Dec; 22(12):2175-2195. PubMed ID: 32440915
[TBL] [Abstract][Full Text] [Related]
6. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
[TBL] [Abstract][Full Text] [Related]
7. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract][Full Text] [Related]
8. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.
Argani P; Laé M; Hutchinson B; Reuter VE; Collins MH; Perentesis J; Tomaszewski JE; Brooks JS; Acs G; Bridge JA; Vargas SO; Davis IJ; Fisher DE; Ladanyi M
Am J Surg Pathol; 2005 Feb; 29(2):230-40. PubMed ID: 15644781
[TBL] [Abstract][Full Text] [Related]
9. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA expression profiling of Xp11 renal cell carcinoma.
Marchionni L; Hayashi M; Guida E; Ooki A; Munari E; Jabboure FJ; Dinalankara W; Raza A; Netto GJ; Hoque MO; Argani P
Hum Pathol; 2017 Sep; 67():18-29. PubMed ID: 28411178
[TBL] [Abstract][Full Text] [Related]
11. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
[TBL] [Abstract][Full Text] [Related]
12. [The translocation carcinoma: A pediatric renal tumor also in adults].
Bruder E; Moch H
Pathologe; 2016 Mar; 37(2):159-65. PubMed ID: 26972595
[TBL] [Abstract][Full Text] [Related]
13. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
[TBL] [Abstract][Full Text] [Related]
14. Adult-onset renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusion with smooth muscle stroma and abnormal vessels.
Kuroda N; Tamura M; Tanaka Y; Hes O; Michal M; Inoue K; Ohara M; Mizuno K; Lee GH
Pathol Int; 2009 Jul; 59(7):486-91. PubMed ID: 19563413
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.
Guo CC; Dancer JY; Wang Y; Aparicio A; Navone NM; Troncoso P; Czerniak BA
Hum Pathol; 2011 Jan; 42(1):11-7. PubMed ID: 21040948
[TBL] [Abstract][Full Text] [Related]
16. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; Molinié V; Escudier B
Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
[TBL] [Abstract][Full Text] [Related]
17. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.
Altinok G; Kattar MM; Mohamed A; Poulik J; Grignon D; Rabah R
Pediatr Dev Pathol; 2005; 8(2):168-80. PubMed ID: 15747097
[TBL] [Abstract][Full Text] [Related]
18. Recurrent gene fusions in prostate cancer: their clinical implications and uses.
Hessels D; Schalken JA
Curr Urol Rep; 2013 Jun; 14(3):214-22. PubMed ID: 23625457
[TBL] [Abstract][Full Text] [Related]
19. Genitourinary cancer in the elderly.
Mulholland SG; Stefanelli JL
Am J Kidney Dis; 1990 Oct; 16(4):324-8. PubMed ID: 2220779
[TBL] [Abstract][Full Text] [Related]
20. FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
